FDA says Ozempic, Wegovy are not in short supply anymore, which could impact prices
The U.S. Food and Drug Administration said Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply. CBS News New York reporter Ali Bauman reports on whether the supply change could lead to consumers paying more.
Until now, it was believed that some drugs used worldwide were the best alternative against certain diseases. However, ...
Keep reading to learn about the common, mild, and serious side effects that Ozempic can cause. For more about the drug, including details about its uses, see this Ozempic overview. Note: ...
People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...
Now, one type of weight-loss medication is proving helpful with another health issue. In a study published Feb. 12 in JAMA ...
A small study confirms observations what users have observed: the medications reduce their cravings for alcohol.
Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...
Ozempic may also help people drink less alcohol. Primary care doctors are concerned about patients accessing GLP-1s through ...
A new case study is the latest to suggest that GLP-1 therapy can tamp down people's unhealthy cravings of drugs like alcohol ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback